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Does Percutaneous Closure
of the Left Atrial Appendage
Prevent Stroke in Atrial Fibrillation?
With great interest we read the study by Ostermayer et al.
concerning percutaneous left atrial appendage (LAA) occlusion
using the PLAATO (percutaneous left atrial appendage trans-
catheter occlusion) system in 111 patients with atrial fibrillation
(AF) (1). Although this technique seems very attractive, several
concerns remain.
1. The investigators state that the PLAATO device has been
shown to be safe and effective in animal experiments. How-
ever, long-term results are still lacking because follow-up data in
6 of 25 dogs of the initial study have not yet been published (2).
2. Transient ischemic attack (TIA) or stroke or embolic risk
factors were criteria for patient inclusion. Thus, it remains
unclear why only stroke and not TIA was regarded a primary
or secondary end point. Were all patients investigated by a
neurologist to look for TIA and stroke at the follow-up visits?
3. When assessing angiographically the adequacy of LAA occlu-
sion, why did the researchers use the proximal and not the
distal dye flow, which appears to be the more logical approach?
Apparently both methods were used, but did they yield the
same results? Why was LAA occlusion assessed as “successful”
also in cases with “mild” or “trace” leaks? The investigators do
not exactly state in how many patients complete LAA occlu-
sion was achieved using the angiographic method.
4. Evaluating the adequacy of LAA occlusion by echocardiogra-
phy, it again remains unclear why mild and trace leaks were
defined as “successful” as it is known from surgical studies that
an incompletely occluded LAA may facilitate thrombus for-
mation and eventually embolism. The data do not show in how
many cases leak size increased, decreased, or if new leaks
developed. Did patients with leaks immediately after the
procedure or during follow-up receive oral anticoagulation?
Overall, complete LAA occlusion was present in only 35% of
patients at one month and 34% at six months, respectively.
5. The 6.6% annual mortality is quite high and exceeds the 4%
found in a previous observational AF study (3). An oversized
PLAATO device owing to its proximity may impair flow in
the circumflex branch of the left coronary artery. Furthermore,
the LAA has hemodynamic and endocrine properties, and
LAA elimination may aggravate heart failure (4). More de-
tailed information about the cardiac deaths, therefore, would
be desirable.
6. Despite “successful” LAA closure, two strokes and three TIAs
occurred. Thus, the annual event rate for stroke and TIA is
5.5%. Because AF is associated with a prothrombotic state (5),
just by closing the LAA not all sites of thrombus formation are
eliminated. In addition, one patient required surgery, and nine
procedure-related serious adverse events occurred in seven
patients, resulting in a complication rate of 6% to 7%.
Overall, the advantage of the PLAATO system in patients with
AF and a contraindication for anticoagulant therapy has not at all
been proven. Because long-term results are lacking, PLAATO at
present cannot be recommended as an alternative to oral anti-
coagulation in AF patients.
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REPLY
We appreciate the interest of Dr. Stöllberger and colleagues in
transcatheter left atrial appendage (LAA) occlusion using the
PLAATO (percutaneous left atrial appendage transcatheter occlu-
sion) system (1). They have raised a number of issues that are
answered below.
1. The 12-month results of the remaining six dogs that were still
alive at the time the initial animal experience was published
confirmed the short-term findings regarding clinical status,
and fluoroscopic, echocardiographic, and macroscopic exami-
nations (Nakai T, personal communication, August 28, 2005).
2. The intention of LAA occlusion is stroke prevention in atrial
fibrillation (AF) patients who are at high risk for ischemic
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